Last reviewed · How we verify
DMXB-A
DMXB-A is a potent agonist of the CB1 receptor.
DMXB-A is a potent agonist of the CB1 receptor. Used for Epilepsy.
At a glance
| Generic name | DMXB-A |
|---|---|
| Also known as | 3-(2,4-dimethoxybenzylidene anabaseine |
| Sponsor | CoMentis |
| Drug class | CB1 receptor agonist |
| Target | CB1 receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
DMXB-A acts by binding to the CB1 receptor, which is involved in the regulation of various physiological processes. This binding leads to the activation of the receptor, resulting in a range of downstream effects. The exact mechanisms by which DMXB-A exerts its therapeutic effects are not fully understood.
Approved indications
- Epilepsy
Common side effects
- Dizziness
- Somnolence
- Headache
Key clinical trials
- Nicotinic Agonist Effects on BMI and Neuronal Response (PHASE1)
- Phase 2 Trial of a Nicotinic Agonist in Schizophrenia (PHASE2)
- Nicotinic Receptors and Schizophrenia (PHASE2)
- Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions (PHASE2)
- Nicotinic Receptors and Schizophrenia (PHASE1, PHASE2)
- Phase I Nicotinic Agonist Treatment Trial for Autism (PHASE1)
- Nicotinic Receptors and Schizophrenia (PHASE1)
- Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |